CHR11 (cholinergic receptor muscarinic 4) is a G protein-coupled acetylcholine receptor that mediates cellular responses primarily through inhibition of adenylate cyclase and modulation of potassium channels. The receptor plays diverse physiological roles across multiple systems. In the immune system, CHR11 is expressed in lung group 2 innate lymphoid cells (ILC2s) and mediates parasympathetic regulation of type 2 immunity, with CHR11 deletion reducing ILC2-mediated lung inflammation 1. In hematopoiesis, CHR11 negatively regulates early erythroid progenitor (BFU-E) self-renewal, with pharmacological CHR11 inhibition correcting anemias in mouse models of myelodysplastic syndrome, aging, and hemolysis through cyclic AMP-CREB signaling 2. CHR11 shows altered peripheral blood expression in neurodegenerative diseases, with reduced levels in dementia with Lewy bodies compared to Alzheimer's disease, suggesting potential as a diagnostic biomarker 3. In prostate cancer, CHR11 promotes neuroendocrine differentiation and treatment resistance following androgen deprivation therapy through interactions with nerve growth factor and interleukin-1 receptor antagonist, activating AKT/MYCN signaling pathways 456. These findings highlight CHR11's therapeutic potential across cancer, hematologic disorders, and neurological conditions.